December 1, 2021

Gastric Neuroendocrine Tumors Epidemiology Forecast Report 2030 | Gastric Neuroendocrine Tumors Epidemiology Analysis 2030 | DelveInsight

3 min read
Gastric Neuroendocrine Tumors epidemiology

Gastric Neuroendocrine Tumors epidemiology

DelveInsight launched a new report on Gastric Neuroendocrine Tumors Epidemiology Forecast, 2030.

DelveInsight’s ‘Gastric Neuroendocrine Tumors Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Gastric Neuroendocrine Tumors epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into tumor”.

Neuroendocrine tumors originate from enterochromaffin cells that are part of the neuroendocrine system of the bronchial and gastrointestinal tract. Based on the anatomic site of origin, NETs originating from the gastric, duodenal, pancreatic, small intestine, appendiceal, colon, and rectal are known as Gastrointestinal NETs.

NET’s are classified as functional or non-functional. Functional tumors make too much of a certain hormone and may cause symptoms. Non-functional tumors may make hormones but do not cause any symptoms. NET’s can also be indolent or aggressive. Indolent implies slow growth of the tumor and aggressive implies rapid growth of the tumor, which tends to spread to other parts of the body. 

Some of the key highlights from the Gastric Neuroendocrine Tumors Epidemiology Report:

  1. According to a study conducted by Yang et al. (2018), titled, “Gastric Neuroendocrine Tumors (G-NETs): Incidence, Prognosis, and Recent Trend Toward Improved Survival,” G-NETs incidence increased from 0.31 per 10,00,000 patients in 1975 to 4.85 in 2014, with an annual percentage change (APCs) of 8.9%. The stage-specific cases were 64.3%, 6.2%, and 11.3% for regional, localized, and distant stages.
  2. Yang et al. (2018) also stated that NETs of the stomach are rare and comprise about 0.1–0.6% of all gastric cancers, and represent about 7% to 8% of all NETs. As per the GLOBOCAN, in 2020, there were 26,259 incident cases of stomach cancers in the US.

Visit for more @ Gastric Neuroendocrine Tumors Epidemiology Insights

Scope of the Gastric Neuroendocrine Tumors Epidemiology report:

  1. The Gastric Neuroendocrine Tumors report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  2. The Gastric Neuroendocrine Tumors Epidemiology Report and Model provide an overview of the risk factors and global trends of Gastric Neuroendocrine Tumors in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  3. The report provides insight into the historical and forecasted patient pool of Gastric Neuroendocrine Tumors in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  4. The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  5. The report assesses the disease risk and burden and highlights the unmet needs of Gastric Neuroendocrine Tumors.
  6. The report provides the segmentation of the Gastric Neuroendocrine Tumors epidemiology

Table of Contents:

  1. Key Insights
  2. Executive Summary of Gastric Neuroendocrine Tumors
  3. Gastric Neuroendocrine Tumors Epidemiology Overview at a Glance
  4. Gastric Neuroendocrine Tumors: Disease Background and Overview
  5. Epidemiology and Patient Population
  6. Case Reports
  7. Country Wise-Epidemiology of Gastric Neuroendocrine Tumors 
  8. Appendix
  9. DelveInsight Capabilities
  10. Disclaimer
  11. About DelveInsight

Read more on Gastric Neuroendocrine Tumors Epidemiological Insights

Related Reports:

Gastric Neuroendocrine Tumors Market

Gastric Neuroendocrine Tumors Pipeline 

Latest Reports by DelveInsight

Biopsy Pipeline Insight, 2020

Colonoscopes Pipeline Insight, 2020

Trastuzumab Biosimilar Insight, 2020

Infliximab Biosimilar Insight

Germany Healthcare Outlook Report, 2020

Spain Healthcare Outlook Report, 2020

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact:

Company Name: DelveInsight Business Research LLP

Contact Person: Kritika Rehani

Email: [email protected]

City: Albany

State: New York

Country: United States



Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.